
    
      GC1102 is a new recombinant hepatitis B immunoglobulin (HBIG) from Chinese Hamster Ovary
      (CHO) cells. It is a monoclonal antibody and has high affinity and avidity to hepatitis B
      surface antigen and several advantages compared to HBIG derived from blood plasma of human
      donors. Volunteers will participate in the study, receive 24-week treatment with
      80,000/100,000 IU of GC1102 or I.V HBIG and be followed up till 28 weeks.
    
  